MX2020013847A - Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo. - Google Patents
Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo.Info
- Publication number
- MX2020013847A MX2020013847A MX2020013847A MX2020013847A MX2020013847A MX 2020013847 A MX2020013847 A MX 2020013847A MX 2020013847 A MX2020013847 A MX 2020013847A MX 2020013847 A MX2020013847 A MX 2020013847A MX 2020013847 A MX2020013847 A MX 2020013847A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal form
- compound
- cdk4
- inhibiting
- activity
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018092194 | 2018-06-21 | ||
| PCT/CN2019/092239 WO2019242719A1 (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013847A true MX2020013847A (es) | 2021-04-28 |
Family
ID=68983152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013847A MX2020013847A (es) | 2018-06-21 | 2019-06-21 | Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12043622B2 (enExample) |
| EP (1) | EP3812386A4 (enExample) |
| JP (1) | JP7430656B2 (enExample) |
| KR (1) | KR102768666B1 (enExample) |
| CN (2) | CN113861191B (enExample) |
| AU (1) | AU2019290722B2 (enExample) |
| BR (1) | BR112020026052A2 (enExample) |
| EA (1) | EA202190036A1 (enExample) |
| IL (1) | IL279579B2 (enExample) |
| MX (1) | MX2020013847A (enExample) |
| PH (1) | PH12020552236A1 (enExample) |
| SG (1) | SG11202012858QA (enExample) |
| TW (1) | TWI786303B (enExample) |
| WO (1) | WO2019242719A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912499B (zh) * | 2021-03-24 | 2026-01-21 | 大陸商貝達藥業股份有限公司 | 藥物組合、包含其的試劑盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN115872923B (zh) * | 2022-12-29 | 2023-04-28 | 成都泰和伟业生物科技有限公司 | 一种化合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016015604A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN104592251B (zh) * | 2015-01-23 | 2019-10-01 | 上海复星医药产业发展有限公司 | 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途 |
| TWI696617B (zh) * | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| WO2017005900A1 (en) * | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2017102796A1 (en) * | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
| TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| KR102543603B1 (ko) * | 2016-12-22 | 2023-06-14 | 베타 파머수티컬 컴퍼니 리미티드 | 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 |
| US11351170B2 (en) * | 2017-08-15 | 2022-06-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Substituted pyrimidines as CDK4/6 inhibitors |
-
2019
- 2019-06-21 IL IL279579A patent/IL279579B2/en unknown
- 2019-06-21 CN CN202111208432.8A patent/CN113861191B/zh active Active
- 2019-06-21 MX MX2020013847A patent/MX2020013847A/es unknown
- 2019-06-21 BR BR112020026052-5A patent/BR112020026052A2/pt unknown
- 2019-06-21 KR KR1020217001384A patent/KR102768666B1/ko active Active
- 2019-06-21 TW TW108121799A patent/TWI786303B/zh active
- 2019-06-21 EP EP19822566.6A patent/EP3812386A4/en active Pending
- 2019-06-21 US US17/254,097 patent/US12043622B2/en active Active
- 2019-06-21 JP JP2020571503A patent/JP7430656B2/ja active Active
- 2019-06-21 WO PCT/CN2019/092239 patent/WO2019242719A1/zh not_active Ceased
- 2019-06-21 CN CN201980037275.3A patent/CN112424202B/zh active Active
- 2019-06-21 EA EA202190036A patent/EA202190036A1/ru unknown
- 2019-06-21 SG SG11202012858QA patent/SG11202012858QA/en unknown
- 2019-06-21 AU AU2019290722A patent/AU2019290722B2/en active Active
-
2020
- 2020-12-21 PH PH12020552236A patent/PH12020552236A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019242719A1 (zh) | 2019-12-26 |
| CN112424202A (zh) | 2021-02-26 |
| US12043622B2 (en) | 2024-07-23 |
| KR20210024004A (ko) | 2021-03-04 |
| EA202190036A1 (ru) | 2021-03-24 |
| CA3104365A1 (en) | 2019-12-26 |
| BR112020026052A2 (pt) | 2021-03-23 |
| TW202016114A (zh) | 2020-05-01 |
| JP7430656B2 (ja) | 2024-02-13 |
| AU2019290722A1 (en) | 2021-01-28 |
| CN113861191A (zh) | 2021-12-31 |
| IL279579B (en) | 2022-10-01 |
| IL279579A (en) | 2021-03-01 |
| SG11202012858QA (en) | 2021-02-25 |
| EP3812386A4 (en) | 2022-03-30 |
| US20210261546A1 (en) | 2021-08-26 |
| IL279579B2 (en) | 2023-02-01 |
| KR102768666B1 (ko) | 2025-02-17 |
| TWI786303B (zh) | 2022-12-11 |
| CN112424202B (zh) | 2021-09-17 |
| CN113861191B (zh) | 2023-09-19 |
| PH12020552236A1 (en) | 2021-06-28 |
| AU2019290722B2 (en) | 2023-12-21 |
| JP2021529175A (ja) | 2021-10-28 |
| EP3812386A1 (en) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2932175C (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| PH12021553238A1 (en) | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors | |
| MX2022008881A (es) | Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico. | |
| NZ588830A (en) | Inhibitors of protein kinases | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| PH12021552760A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| WO2007040438A3 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| MX2014013957A (es) | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). | |
| TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| MY206359A (en) | Heteroaryl-substituted pyrazole compound and medicinal use thereof | |
| WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| MX2016012669A (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1. |